Introduction
The fluoroquinolone antibacterials are currently accepted as valuable broad-spectrum agents, suitable for use in both community and hospital settings. The class as a whole is characterized by good antibacterial activity after oral administration and, at least historically, by better p e r f o rmance against Gram-negative organisms than Grampositive pathogens. This field has been recently reviewed.
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Quinolone mechanism of action
Quinolones exert their antibacterial action via inhibition of the type II topoisomerase DNA gyrase, an essential bacterial enzyme which alters the topology of doublestranded DNA within the cell. 3 In most bacteria, the chromosome exists as a single circle of double-stranded DNA, which is maintained in a highly negatively supercoiled state; this energetically activated form is required for critical cellular processes such as replication and transcription. DNA gyrase, an A 2 B 2 tetramer, is the only enzyme that can effect supercoiling of DNA, which it carries out by cleaving both strands of DNA, passing another double strand of DNA through the break, and resealing the broken ends, in an interative process. Inhibition of this activity by fluoroquinolones is associated with rapid killing of the bacterial cell. While the detailed mechanism of this bactericidal action is still not completely understood, some aspects of the inhibitory activity have been elucidated. Quinolones bind to a gyrase-DNA complex, in which the first step of the gyrase enzymatic reaction has taken place: the double-stranded DNA has been cleaved, resulting in temporary covalent bonding of the 5 phosphates of the two strands to the Tyr-122 residues on the two A subunits of the enzyme. This is often termed the 'cleavable complex', as the broken DNA can be visualized on a gel after detergent treatment. This ternary complex of DNA, enzyme and drug is relatively stable, and prevents the resealing of the broken DNA strands. It has been postulated that the ternary complex serves as a cellular poison, by blocking the passage of polymerases on the DNA strand, a theory which has recently received experimental support. 4 An interpretation of this type is particularly appealing in that it provides an explanation for the apparent disparity between quinolone potencies at the enzymatic and cellular levels. It has been observed repeatedly that MICs of quinolones for intact bacteria can be much lower than concentrations required to inhibit the gyrase enzyme from the same organism.
merase, topoisomerase IV, have led to the suggestion that, in Gram-positive organisms, topoisomerase IV, rather than DNA gyrase, may be the primary target for some quinolones (see below).
Further subtleties in the bactericidal mechanism of action of quinolones have been investigated. All quinolones have the same basic mechanism of action, called mechanism A, which requires RNA and protein synthesis, as well as cell division, for bactericidal action. A number of newer quinolones also exhibit mechanism B, the ability to kill non-dividing bacteria without concomitant protein or RNA synthesis. A few quinolones retain bactericidal activity in the absence of bacterial multiplication, yet still require active protein or RNA synthesis. This is termed mechanism C. 5 Interestingly, the utilization of mechanisms beyond mechanism A can be dependent on the organism in question: ciprofloxacin displays both mechanisms A and B against Escherichia coli, but only mechanism A against Staphylococcus aureus. 
Resistance to quinolones
Resistance to quinolone antibacterials can be mediated at the level of the cytoplasmic and outer membranes. Mutations leading to a decrease in porin expression in the outer membrane of Gram-negative bacteria, as well as expression of marA, a transcriptional activator involved in multiple antibiotic resistance, result in decreased accumulation of quinolones and therefore lowered susceptibility. Energy-dependent efflux mechanisms of resistance, through which quinolones are actively pumped out of the cell, have been characterized in both Gram-positive and Gram-negative bacteria. These resistance mechanisms seem to affect quinolone agents to different extents, depending on the physical properties of the individual quinolones. 7 Alteration of the target enzyme, DNA gyrase, however, appears to be the more dominant factor in expression of resistance to quinolones. Residues 67-106 of the A subunit of DNA gyrase have been termed the quinolone resistance determining region (QRDR), since a number of mutations in this region confer quinolone resistance. In general, mutations of this type result in increased MICs of all quinolones. 7 Topoisomerase IV mutations seem to be of importance in Gram-positive organisms (see below).
Activity of quinolones against other topoisomerases
The action of quinolones has been studied against other topoisomerases, such as topoisomerase IV, which has been discovered recently in bacteria. 8 This enzyme also modifies the topology of double-stranded DNA, but while DNA gyrase seems to be important for maintenance of supercoiling, topoisomerase IV is predominantly responsible for separation of daughter DNA strands during cell division. The presumed similarity in the enzymatic mechanism for DNA strand passage between DNA gyrase and topoisomerase IV led investigators to examine the activity of quinolones against this new enzyme. Indeed, quinolones do inhibit topoisomerase IV from E. coli, but at concentrations two-to 30-fold higher than those effective against DNA gyrase from the same species. [9] [10] [11] Examination of mutations in quinolone-resistant clinical isolates of E. coli revealed that topoisomerase IV may be a secondary target for fluoroquinolones. 12 Against Grampositive organisms, however, topoisomerase IV is likely to be a primary target of quinolones. Resistance studies with S. aureus have shown that upon exposure to concentrations of ciprofloxacin above the MIC, mutations arise first in topoisomerase IV, followed by a second mutation in DNA gyrase which confers a higher level of resistance. 13 The potential for quinolone inhibition of eukaryotic topoisomerase II has also received significant attention. Quinolone structural features that can result in potent inhibition of this important mammalian congener of DNA gyrase have now been identified. 14 Various studies have shown that inhibition of topoisomerase II correlates with cytotoxicity and, in some cases, can result in observable anti-tumour activity in vivo. 15 For a compound to be used as an antibacterial agent, selectivity for the bacterial enzyme DNA gyrase (and perhaps topoisomerase IV) is desirable.
Quinolones
Thousands of quinolone agents have been prepared and evaluated over the last three decades. The original member of the quinolone class of antibacterial agents is nalidixic acid (Figure 1 ), an agent exhibiting exclusively Gram-negative activity, which was discovered at SterlingWinthrop. 16 Little systemic distribution is observed, but high concentrations are attained in the urine; nalidixic acid is therefore used primarily for urinary tract infections. The newer fluoroquinolones arose with the development of norfloxacin, 17 which combined structural features of flumequine (C-6 fluorine atom) and pipemidic acid (C-7 piperazine side chain). Norfloxacin exhibits activity against Gram-positive pathogens, in addition to the Gram-negative activity observed in all the quinolone agents described at the time. 17 Because of poor oral absorption and low blood concentrations, norfloxacin is approved only for urinary tract and sexually transmitted diseases. Introduction of N-methyl piperazine at the C-7 position of a tricyclic benzo x a z i n e nucleus produced ofloxacin, which exhibits improved in-vitro activity over norfloxacin while also yielding good systemic exposure. This agent is therefore approved for lower respiratory tract and skin infections, in addition to urinary tract infections, sexually transmitted diseases and prostatitis. In another modification of the norfloxacin structure, replacement of the ethyl group on the nitrogen at position 1 by a cyclopropane produced ciprofloxacin, which exhibits substantially heightened activity against both Gram-positive and Gram-negative bacteria. Importantly, this modific a t i o n also improved oral absorption and systemic distribution, leading to the use of ciprofloxacin for various tissue infections, such as those in skin and soft tissue, bone, joints and the lower respiratory tract, as well as for urinary tract infection. A more recent quinolone agent is sparfloxacin (Figure 1 ), which bears two cis-oriented methyl groups on the piperazine and an additional C-5 amino group and C-8 fluorine on the cyclopropyl quinolone nucleus. These modifications provide improvements over ciprofloxacin against Gram-positive and anaerobic organisms. 18 Despite their wide usage, the spectrum and characteristics of the currently available quinolone drugs do provide room for improvement. While the Gram-negative activity of ciprofloxacin is excellent, this compound exhibits relatively low intrinsic activity against a number of Grampositive organisms, such as Streptococcus pneumoniae. Given the high incidence of this organism in respiratory tract infections and meningitis, enhanced activity against S. pneumoniae is an important target for new quinolone agents. Anaerobes are also not particularly sensitive to the older quinolones such as ciprofloxacin and ofloxacin. The potential for improved convenience of dosaging also exists; both ciprofloxacin and ofloxacin are administered two or three times per day.
A number of adverse effects have also been observed with various members of the fluoroquinolone family. 19, 20 Theophylline interactions arise through inhibition of cytochrome P450 enzymes by some fluoroquinolones, resulting in undesirably high systemic concentrations of theophylline, which can lead to CNS symptoms including convulsions. This drug interaction has been a problem for enoxacin and, to a lesser extent, ciprofloxacin. Phototoxicity of quinolones has become important clinically, particularly for compounds bearing a halogen atom at C-8, such as lomefloxacin, fleroxacin and sparfloxacin. 20 . Quinolones are not currently approved for paediatric applications (with one exception being norfloxacin in Japan), because of the articular cartilage damage seen in the joints of immature animals after quinolone administration. A number of reports of compassionate use of quinolones in paediatric patients, however, have described successful treatment without good evidence for chondrotoxicity. 21 Extensive efforts in the synthesis of new compounds in this class have been made by both industrial and academic laboratories, in attempts to optimize the biological activity of the quinolones while simultaneously minimizing adverse effects. 2, 20, 22 Through this research, the breadth of allowable structural modification has been defined, while a number of optimal structural features have been kept relatively constant (Figure 2 ). The nitrogen at N-1 and carboxylic acid at C-3 are almost indispensable for activity, although there are a few examples of alterations that retain antibacterial activity. C-2 can only be substituted as part of an additional ring, while the ketone at C-4 seems to be inviolable. The fluorine at C-6, which has become a part of the class name, is very important for potent activity. Thus, the pyridone ring and the C-6 fluorine are unchanged in almost all quinolone agents, as indicated in Figure 2 . As mentioned above, variable substitution is tolerated on the N-1 nitrogen, although most recently reported quinolones bear a cyclopropyl or aryl group at this position. The 5-position and 8-position can be unsubstituted, or bear relatively small substituents, commonly amine or methyl groups at the 5-position, and a halogen or methoxy group at the 8-position. The 8-position can also be occupied by a nitrogen atom, giving a naphthyridone nucleus. The most intensive structural variation has been carried out on amines at the 7-position, partially due to the ease of their introduction through a nucleophilic aromatic substitution reaction on the corresponding halide. Piperazine, aminopyrrolidine, and their substituted derivatives have been the most successfully employed side chains, as evidenced by the compounds currently on the market.
Trovafloxacin
Structure-activity relationships
Trovafloxacin (CP-99,219, Figure 3 ) was discovered in the course of a research programme whose goal was to discover a quinolone agent with pharmacokinetics appropriate for once-daily dosing and improved activity over ciprofloxacin against Gram-positive pathogens. 23 It was found that cyclopropyl-fused pyrrolidines (specifically amino-and aminomethyl-substituted 3-azabicyclo[3.1.0]-hexanes, Figure 4 ) served as promising C-7 substituents for quinolone antibacterials. These novel C-7 substituents all provided in-vitro Gram-positive activity generally superior to that of ciprofloxacin. Several important differences were noted, however, between the amino-substituted derivatives (Figure 4a , c) and their aminomethyl congeners (Figure 4b, d ). Amino-substituted analogues were generally more potent against Gram-negative organisms in vitro than aminomethyl analogues. An additional difference between the series became apparent during in-vivo studies: in both murine protection models and monkey pharmacokinetic studies, the amino derivatives tended to yield superior results.
Variations at N-1 and the 8-position were also investigated. The N-1 o,p-difluorophenyl group provided Grampositive activity superior to that obtained with an N-1 cyclopropyl group for analogues bearing aminomethyl side chains, but provided less or no improvement in the activity for the lower homologues substituted with an amino group. The effect of quinolone (CH at the 8-position) versus naphthyridone (N at the 8-position) was most pronounced in a pharmacokinetic study carried out in the cynomolgus monkey with a set of agents bearing the amino side chain C (Figure 4) . For both N-1 cyclopropyl and o,p-difluorophenyl analogues, the naphthyridones outperformed the quinolone analogues, in half-life, C max and AUC (Table I ). The N-1 o,p-difluorophenyl naphthyridone trovafloxacin stood out in these studies, providing the longest half-life observed in the entire series.
The improved pharmacokinetics of trovafloxacin contrast with those of tosufloxacin ( Figure 5 ), a quinolone agent marketed in Japan that exhibits relatively low blood concentrations and a short half-life in humans (C max of 0.56 mg/L after 150 mg dose, half-life 4.0 h). 24 The difference between these two agents lies in the C-7 substituent, perhaps most significantly in the position and character of the distal amino group. From the X-ray crystal structures (see below), the distal amino group in trovafloxacin is somewhat further from the naphthyridine nucleus than that of tosufloxacin, as measured by the distance between the two nitrogen atoms in the sidechains (trovafloxacin, 4.2 Å; tosufloxacin, 3.1 Å). Additionally, the fused cyclopropane of the C-7 substituent of trovafloxacin could exert a significant effect on the basicity of the pendant primary amino group, compared with that of the corresponding amino group in tosufloxacin (see below).
Support for the importance of the positioning of the distal amino group was obtained by inversion of the stereochemistry of the amino group in trovafloxacin ( Figure 6 ). While compound 1 gave antibacterial activity only slightly less potent than that of trovafloxacin, it provided inferior efficacy and pharmacokinetics in animal models. 23 The basicity of the primary amine could also affect the in-vivo performance: in a model system where the quinolone nucleus is replaced by a benzyloxycarbonyl group, the endo-amine 2 was found to exhibit a basicity of 0.6 pK a units less than that of the exo-amine 3 used in trovafloxacin. Both compounds were less basic than the related aminopyrrolidine 4 from tosufloxacin ( Figure 7 ).
Physicochemical properties
Trovafloxacin was chosen for clinical development on the basis of its long half-life and potent broad-spectrum activity against pathogens including S. pneumoniae and 5 Figure 5 . Structure of tosufloxacin. Table I . Pharmacokinetics of C-7 3-azabicyclohexyl derivatives (monkey, 20 mg/kg po) anaerobes (see 'Biological profile' below). Trovafloxacin is under development as the mesylate salt, a white to offwhite crystalline powder, whose physicochemical properties are given in Table II . The nitrogen atom at the 8-position (Figure 3 ) renders trovafloxacin technically a naphthyridone, but this ring system falls under the general class name of quinolone antibacterials. At the N-1 position is a 2,4-difluorophenyl group. The unusual bicyclic diamine substituent at C-7 contributes to the excellent biological properties of this drug (see above). Stereochemistry is indicated about this ring system to unambiguously represent the relative orientation of the exocyclic amino group with respect to the hydrogens at the ring fusion. However, a plane of symmetry exists in this fused bicyclic skeleton, which renders trovafloxacin achiral.
From the X-ray crystal structure of trovafloxacin (Figure 8 ), it can be seen that the o,p-difluorophenyl group at N-1 is twisted out of the plane of the naphthyridone nucleus. A crystal structure of tosufloxacin ( Figure 5 ), which shares with trovafloxacin the N-1 difluorophenyl naphthyridone nucleus, exhibits a similar degree of twisting out of plane (J. Bordner, personal communication). This phenomenon has been predicted computationally through energy minimization calculations on the rotamers about the N-phenyl bond. 25 Two energy minima were predicted, for the conformations in which the angle between quinolone and phenyl rings is 70° or 100°, the latter of which is in good agreement with the trovafloxacin crystal structure. The bicyclic amine at C-7, however, is oriented so that the naphthyridone nucleus and the pyrrolidine ring of the C-7 substituent are roughly coplanar. As expected for a salt, the methanesulphonate anion is in close proximity to the positively charged primary amino group on the azabicyclo[3.1.0]hexane side chain.
The aqueous solubility of trovafloxacin in water is 23 g/L, with a saturated solution giving a pH of 3.5. Like most quinolones, 26 the solubility curve for trovafloxacin is 'U-shaped', with the minimum solubility observed around pH 7 (Figure 9 ). At physiological pH, therefore, it exhibits a relatively low solubility of 15 mg/L. The Lalanyl-L-alanine derivative, alatrofloxacin (Figure 10 ), is much more soluble in water than trovafloxacin (equivalent to 22 g/L of trovafloxacin at physiological pH, Figure  9 ) and is rapidly cleaved to the parent agent in vivo. 27 It is effective as an iv formulation of trovafloxacin and is therefore also under development.
The pK a values for trovafloxacin, measured via potentiometric titration, are given in Table II . The value of 5.87 corresponds to the pK a of the carboxylic acid and is typical of the value obtained for various other quinolone agents. 28 Ciprofloxacin, examined by the same analytical procedure, gave a pK a of 6.18. The pK a of the amino group of trovafloxacin was determined to be 8.09, compared with 8.66 for ciprofloxacin.
Trovafloxacin is relatively lipophilic, exhibiting a distribution coefficient of 1.9 at pH 6.5 (logD pH6.5 0.28). Ciprofloxacin, an example of a relatively hydrophilic quinolone, gave a partition coefficient of 0.3 (logD pH6.5 0.52) under the same conditions (A. Campeta & E. Fiese, personal communication).
Trovafloxacin can be analysed by HPLC with UV detection. 29 It exhibits excellent chemical stability under most conditions. As for all quinolones, this agent should be stored in light-resistant containers. 
Biological profile
In-vitro activity. The in-vitro spectrum of trovafloxacin is characterized by markedly improved activity over ciprofloxacin against Gram-positive cocci and anaerobes, w h i l e generally maintaining the good activity of ciprofloxacin against Gram-negative pathogens. [30] [31] [32] [33] Trovafloxacin has a high intrinsic activity against staphylococci which are sensitive to the fluoroquinolones, with MIC 90 s in the range of 0.015-0.5 mg/L. This activity is better than that of ciprofloxacin (Table III) 1-8 mg/L trovafloxacin. 32, [34] [35] [36] [37] Trovafloxacin is about ten-fold more potent than ciprofloxacin and two-to eightfold more potent than sparfloxacin against streptococci, including S. pneumoniae. 2, 38 As illustrated in other articles in this volume, trovafloxacin is equally active against penicillin-sensitive and penicillin-resistant pneumococci. In common with other fluoroquinolones, trovafloxacin is less active against enterococci, but MIC 90 s in the range of 0.25-2 mg/L have been reported for Enterococcus faecalis in most studies. 32, 39, 40 It should be pointed out, however, that some collections of E. faecalis and Enterococcus faecium have MIC 90 s of trovafloxacin of 8 mg/L. 40, 41 Trovafloxacin also has potent activity against other important respiratory pathogens. It is similar in activity to ciprofloxacin and sparfloxacin against Haemophilus influenzae, Moraxella catarrhalis and Legionella pneumophila (Table III) . It is at least four-fold more active than ofloxacin against Mycoplasma pneumoniae.
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The improvements in activity of trovafloxacin against Gram-positive organisms are balanced by its activity against Enterobacteriaceae, which is equal to or only two-fold less than that of ciprofloxacin; MIC 90 s of trovafloxacin are 0.03-4.0 mg/L for ciprofloxacin-sensitive E. coli, and 0.01-1.0 mg/L for Klebsiella pneumoniae, Enterobacter cloacae and Citrobacter freundii. 33, 36, 43, 44 Against Pseudomonas aeruginosa, reported MIC 90 s of trovafloxacin, ciprofloxacin, and sparfloxacin range from 1-16, 0.5-16, and 1-8 mg/L, respectively. 2, [43] [44] [45] Trovafloxacin also has better activity than ciprofloxacin against some ciprofloxacin-resistant organisms, such as strains of Neisseria gonorrhoeae and methicillin-resistant S. aureus (MRSA). A study at the Centers for Disease Control and Prevention found that trovafloxacin exhibited activity equivalent to or two-fold greater than that of ciprofloxacin against ciprofloxacin-sensitive strains of N. gonorrhoeae. Against strains that are less sensitive to ciprofloxacin (MIC 90 0.5 mg/L), trovafloxacin exhibited enhanced activity, with an MIC 90 of 0.06 mg/L. Furthermore, against three isolates with ciprofloxacin MICs of 2 mg/L, the MIC of trovafloxacin for all three was 0.25 mg/L. 46 Many MRSA strains are now resistant to fluoroquinolone agents, with 80% of hospital isolates having elevated ciprofloxacin MICs. Trovafloxacin, as mentioned above, has lower MICs against MRSA than ciprofloxacin, although such concentrations may not be readily achieved in serum (Table III) .
A major advantage of trovafloxacin is its improved activity over other currently marketed fluoroquinolones against anaerobes. Data from one typical study 47 indicate that trovafloxacin is 32-fold more active than ciprofloxacin against isolates of Bacteroides fragilis (Table IV) 0.5 and 64 mg/L for this collection of anaerobes. 47 Trovafloxacin was up to 128-fold more active than cefoxitin and from two-to 64-fold more active than metronidazole against these strains.
The MBC of trovafloxacin is generally equal to or twofold higher than the MIC. This remains true over a range of pH and growth media conditions. 43, 48 Compared with previous quinolones, such as ciprofloxacin and ofloxacin, trovafloxacin has enhanced bactericidal activity against S. aureus. A recent study determined that trovafloxacin, in addition to mechanism A, has marked mechanism B activity against S. aureus. 49 This may contribute to the enhanced bactericidal activity against this pathogen.
The selectivity and mechanism of action of trovaflo x a c i n were investigated by examining its activity against various topoisomerases in assays that measure DNA cleavage. As expected, trovafloxacin exhibited potent activity against E. coli DNA gyrase, showing a minimal effective concentration of 0.78 mg/L, but proved very inactive against calf thymus topoisomerase II, with an IC 50 1000 mg/L. 48 These data reflect the excellent selectivity of trovafloxacin for the bacterial enzyme. As observed with other fluoroquinolones, trovafloxacin was 2.4-fold less potent at inhibiting the decantenation activity of E. coli topoisomerase IV (IC 50 1.9 M) than it was against the supercoiling activity of DNA gyrase (IC 50 0.8 M) (T. D. Gootz, unpublished results).
As mentioned above, recent data from several laboratories indicate that, in contrast to the situation in Gramnegative organisms, topoisomerase IV in Gram-positives serves as a primary target of fluoroquinolones. 13 In S. aureus, mutations leading to moderate levels of fluoroquinolone resistance occur in topoisomerase IV, rather than in DNA gyrase. In studies with S. pneumoniae, selection of resistance with trovafloxacin occurred in vitro at a frequency of 8.9 10 9 when clinical strains were plated on medium containing antibiotic concentrations from 1 to 4 mg/L. 50 Mutation frequencies for resistance to ciprofloxacin ranged between 1.8 10 5 and 1. 7 10 9 over the same concentration range. 50 First-step mutants selected with ciprofloxacin had changes in the A subunit of topoisomerase IV (GrlA) involving substitution of Phe or Tyr at Ser80. It is noteworthy that while these mutants had MICs of ciprofloxacin of 4-8 mg/L, they were still inhibited by 0.5 mg/L of trovafloxacin (Table V) . The low frequency of emergence of resistance to trovafloxacin observed in S. pneumoniae in vitro and the potent activity retained against topoisomerase IV mutants of this species highlight the advantage of this new agent in comparison with ciprofloxacin.
Activity in animal models of infection. The marked improvements in the activity of trovafloxacin in comparison with other fluoroquinolones have been confirmed in several animal infection models in which the drugs were administered therapeutically against key pathogens such as S. pneumoniae, L. pneumophila and B. fragilis. In a murine pneumococcal pneumonia model, trovafloxacin was more effective than temafloxacin (PD 50 2.1 mg/kg and 29.5 mg/kg, respectively), while ciprofloxacin failed (PD 50 100 mg/kg). 51 Trovafloxacin, administered iv as the prodrug alatrofloxacin, had bactericidal activity comparable to that of ceftriaxone and vancomycin in rabbit models of both penicillin-sensitive and penicillin-resistant S. pneum o n i a e m e n i n g i t i s . 5 2 , 5 3 For the treatment of L. p n e u m o p h i l a pneumonia in guinea pigs, intraperitoneal alatrofloxacin proved effective at dosages (expressed in terms of trovafloxacin) as low as 1.4 mg/kg/day. 54 In mixed aerobic/anaerobic infections (either B. fragilis and S. aureus or B. fragilis and E. coli) in mice, trovafloxacin 9 (15) , P. magnus (16) , P. micros (3), P. anaerobius (11) , P. tetradius (14) , P. hydrogenalis (1), Peptostreptococcus sp. (1) and P. intermedius (2) .
reduced the numbers of recoverable cfu of both organisms ( 100-1000-fold), while ciprofloxacin, vancomycin, metronidazole, cefoxitin and ceftriaxone failed.
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Metabolism. The major circulating metabolite of trovafloxacin in humans is the ester glucuronide 5 ( Figure  11) , with the N-acetyl derivative 6 and the N-acetyl ester glucuronide 7 also present. 55 N-acetyl trovafloxacin 6 has intrinsic in-vitro antibacterial activity, although it is at least ten-fold less active than trovafloxacin against a range of Gram-positive and Gram-negative organisms.
Phase I clinical and pharmacokinetic studies. Multipledose pharmacokinetic studies in humans 56 have confirmed the excellent pharmacokinetics observed in animal models and human single-dose trials. 57 Trovafloxacin exhibits linear and stationary pharmacokinetics, and is rapidly absorbed in man after oral dosing, with a T max of approximately 1 h. The mean elimination half-life of approximately 10 h is appropriate for once-daily dosing, with a C max of 1 mg/L for the 100 mg dose level and 3 mg/L for the 300 mg dose. 56 The oral bioavailability, by comparison with iv administered alatrofloxacin, was found to be 87.6% and unaffected by ingestion of food. 58 The mean volume of distribution of 1.3 L/kg indicates good tissue distribution. 59 Consistent with this, the concentration in bronchial cells after a single dose of trovafloxacin was three times higher than the serum concentration. 60 No substantial difference in pharmacokinetics was observed between male and female subjects or between elderly and young subjects. 61 The CNS penetration of trovafloxacin has been examined in children, to establish its potential for use in bacterial meningitis. For 21 paediatric patients, aged 1-12 years, infusion of 180 mg/m 2 of alatrofloxacin gave peak CSF concentrations of trovafloxacin up to ten-fold the MIC 90 for S. pneumoniae. Significantly, these results reflect antibiotic penetration through non-inflamed meninges. 62 There are important pharmacokinetic differences between trovafloxacin and the older quinolones. The serum protein binding of trovafloxacin was found to be 70%, significantly higher than that of the older quinolones. 57 While earlier quinolones are generally excreted in the urine, high levels of trovafloxacin were found in the bile of rats and dogs, indicating that elimination is primarily via biliary excretion. 63, 64 In humans, only 5% of the trovafloxacin dose was renally excreted as unchanged drug. 56 However, urine concentrations at 0-2 h are still many times higher than the MICs for most urinary tract pathogens. Even at 12-24 h after the 100 mg doses, the urine concentration in humans is 2 mg/L, making trovafloxacin potentially useful for the treatment of urinary tract infections. These observations suggest that trovafloxacin dosages may not need to be adjusted in renally impaired patients. Good tissue distribution was observed in rats, dogs and monkeys. In mice, lung concentrations of trovafloxacin after oral administration were substantially greater than those of ciprofloxacin or temafloxacin: the AUC for trovafloxacin was three to six times larger than those of the two reference antibiotics. 51 This correlates well with human serum data: the AUC for a single 300 mg dose of trovafloxacin was approximately four-fold greater than that observed for ciprofloxacin given as a single 500 mg dose. 57 The improved pharmacokinetic characteristics and expanded spectrum of trovafloxacin suggest that this new fluoroquinolone could be used to treat infections that are not well covered by earlier agents in this class. In uncomplicated lower urinary tract infection, trovafloxacin given orally for a week at 100 or 200 mg/day was as efficacious as 500 mg/day ciprofloxacin (McCarty, J. M., Gooch, W. M., Gilderman, L., Pancorbo, S., et al., personal communication). Eradication rates were 93% with all three regimens. Trovafloxacin has also been examined for efficacy in the treatment of respiratory tract infections. In studies of acute, uncomplicated, community-acquired pneumonia, oral trovafloxacin 200 mg od given for 10 days was comparable to cefaclor 500 mg tds given for the same period (Rodriguez, G., Pace, S., Gezon, T. & Pancorbo, S., personal communication). Rates of clinical response (cure plus improvement) were similar in each group, with few clinical relapses observed during post-treatment follow-up up to day 25. The efficacy of trovafloxacin compared with ofloxacin was measured in patients with acute exacerbations of chronic bronchitis (Chodosh, S., Rodriguez, G., Pancorbo, S., et al., personal communication). Trovafloxacin was administered orally at either 100 or 300 mg od dosages for 10 days, compared with oral ofloxacin 400 mg bd for the same period. Clinical and bacteriological efficacy at the end of treatment was similar with each regimen, with clinical success rates being 97%.
Results of early clinical trials with trovafloxacin were highly encouraging and an extensive phase III programme has been completed (S. Hopkins, personal communication).
Adverse effects. Trovafloxacin was well tolerated in multiple-dose oral studies at 100 and 300 mg, with few adverse effects at the 100 mg dose, and lightheadedness and headache the most frequently reported side-effects at the 300 mg level. No clinically significant changes in any clinical chemistry or haematological parameters were observed. 56 Trovafloxacin is predicted to exhibit a low level of adverse reactions relating to photosensitivity and theophylline interaction. Photosensitivity studies in mice at doses up to 250 mg/kg indicated that trovafloxacin produced only limited erythema and ear thickening, compared with lomefloxacin, which produced a strong and persistent phototoxic response at doses of 71 mg/kg or higher. 65 A drug interaction study carried out in healthy male volunteers indicated that trovafloxacin has no effect on the steady-state pharmacokinetics of theophylline. 66 
Conclusions
Trovafloxacin is a new naphthyridone agent of the fluoroquinolone class, which provides advantages in spectrum and pharmacokinetic properties over both older agents such as ciprofloxacin and the newer fluoroquinolone sparfloxacin. Against Gram-positive organisms, including S. pneumoniae and penicillin-resistant S. pneumoniae, trovafloxacin is substantially more active than cipro- floxacin, while generally retaining ciprofloxacin's marked Gram-negative activity. Notably, the low MIC 90 s of trovafloxacin for respiratory tract pathogens combined with its pharmacokinetic profile may extend the clinical utility of this new agent beyond that established for older fluoroquinolones. This should translate into important applications in treatment of upper and lower respiratory tract infections. The activity of trovafloxacin against anaerobes exceeds that of sparfloxacin 2 and is markedly better than that of older quinolone agents such as ciprofloxacin; animal studies have shown good efficacy in treating mixed aerobe/anaerobe infections. Unlike sparfloxacin, which achieves relatively low blood concentrations and has non-dose proportional kinetics in humans, 32 trovafloxacin studies in humans have demonstrated dose-proportional pharmacokinetics. With both oral and iv formulations, trovafloxacin offers flexible dosaging options and, like sparfloxacin, has an extended half-life, appropriate for once-daily dosing. Neither agent affects the pharmacokinetics of theophylline, 67 but while sparfloxacin has been shown to produce phototoxic effects in mice at relatively low doses, 20 murine studies with trovafloxacin indicate little or no phototoxic effect. Trovafloxacin has been well tolerated in clinical trials, and results from phase II/III studies show therapeutic efficacy over the broad range of infectious agents discussed in this review.
